Hikal Ltd reported a significant reduction in consolidated losses to Rs 61 million for the quarter ended September 30, 2026, compared to Rs 349 million in the year-ago period. Revenue climbed to Rs 4,342 million, fueled by growth in both its pharmaceutical and crop protection divisions. While the company is showing improved operational efficiency, investors should remain cautious of the ongoing Supreme Court litigation regarding environmental compliance and the lingering impact of a USFDA warning letter on pharma sales.
Hikal Ltd Q2 Performance Update
Revenue at Rs 4,342 million, Loss at Rs 61 million.
Reader Takeaway: Revenue growth across segments is driving a recovery, but legal and regulatory overhangs persist for the firm.
What just happened
Hikal Ltd has posted its unaudited financial results for the quarter ended September 30, 2026. The company successfully reduced its consolidated loss to Rs 61 million from Rs 349 million in the same quarter last year. Total revenue from operations saw a significant uptick, rising to Rs 4,342 million from Rs 3,185 million, indicating a strong top-line recovery.
Segment Performance
The Pharmaceuticals segment recorded revenue of Rs 2,778 million, up from Rs 1,895 million. Meanwhile, the Crop Protection and Specialty Ingredients segment contributed Rs 1,564 million, compared to Rs 1,290 million in the previous year's second quarter.
Governance and Risks
Hikal Ltd continues to manage a legal dispute regarding environmental non-compliance. The matter is currently before the Supreme Court, which has stayed a recovery order of Rs 174.5 million. No financial provisions have been made for this litigation. Additionally, management acknowledged that the USFDA warning letter issued in August 2025 continues to exert pressure on the pharmaceutical division’s operational capabilities.
What to track next
Investors should monitor updates regarding the Supreme Court hearing and any progress in resolving the USFDA regulatory status. These two factors remain the primary risks to the company's financial stability and operational growth trajectory.